info@example.com

+1 66589 14556

Metastatic Prostate Cancer Explained

Metastatic Prostate Cancer Explained

📖 7 min read Written and medically reviewed by Dr. Alhad Naragude, MBBS, MS, DrNB Urology Last updated: September 6, 2026

Metastatic prostate cancer means cancer cells have spread beyond the prostate and regional tissues to distant sites, most commonly bone and lymph nodes. It is usually treated as a systemic disease. Androgen deprivation therapy (ADT) remains the foundation because prostate cancer is strongly driven by androgen signalling, but for most fit men with newly diagnosed metastatic hormone-sensitive disease, ADT alone is no longer the preferred endpoint. Treatment is commonly intensified with an androgen-receptor pathway inhibitor and, in selected patients, docetaxel chemotherapy as part of doublet or triplet therapy. Modern imaging, molecular testing and supportive care have expanded the number of treatment options and can meaningfully prolong disease control.

Where does prostate cancer commonly spread?

  • Bones, especially the spine, pelvis, ribs and proximal long bones.
  • Lymph nodes outside the immediate pelvic region.
  • Lungs or liver in more advanced disease.
  • Other organs less commonly.

Bone metastases can cause pain or fracture, but some metastatic disease is found on staging scans before symptoms develop.

What does hormone-sensitive vs castration-resistant mean?

Term Meaning Why it matters
Metastatic hormone-sensitive prostate cancer (mHSPC) Cancer is metastatic and still responds to testosterone suppression Initial therapy uses ADT plus treatment intensification.
Metastatic castration-resistant prostate cancer (mCRPC) Cancer progresses despite testosterone being maintained at castrate level Treatment changes to additional hormonal agents, chemotherapy, radioligand therapy, targeted therapy or other options depending on prior treatment and molecular features.

How is metastatic disease diagnosed and staged?

PSMA PET/CT is increasingly used because it can detect prostate-cancer deposits at lower disease burden than conventional imaging. CT and bone imaging still have roles. Biopsy is usually already available from the prostate or metastatic site. Baseline tests also assess blood counts, kidney and liver function, alkaline phosphatase, testosterone and symptoms.

First-line treatment

Androgen deprivation therapy (ADT)

ADT lowers testosterone using GnRH agonists, GnRH antagonists or surgical orchiectomy. Choice depends on urgency, cardiovascular profile, availability, preference and treatment plan.

Androgen-receptor pathway inhibitors

Agents that more completely block androgen production or receptor signalling are commonly added to ADT because combination therapy improves outcomes compared with ADT alone in appropriate patients.

Chemotherapy and triplet treatment

Docetaxel may be added in selected fit patients, especially when disease volume is high or other features favour early chemotherapy. In appropriate men, ADT plus docetaxel plus an androgen-receptor pathway inhibitor can be considered as triplet therapy.

Bone and general health during treatment

  • Weight-bearing and resistance exercise where safe.
  • Assessment of calcium/vitamin D intake and fracture risk.
  • Bone-density testing when indicated, particularly during prolonged ADT.
  • Monitoring blood pressure, glucose, lipids, weight and cardiovascular risk.
  • Prompt treatment of pain and evaluation of fracture or spinal-cord-compression risk.

Emergency symptoms

New severe back pain with leg weakness, numbness, saddle anaesthesia or bladder/bowel dysfunction may indicate spinal cord compression. Seek emergency care immediately. Inability to pass urine, uncontrolled pain, pathological fracture or severe weakness also warrants urgent assessment.

Why treatment is intensified early

For most fit men presenting with metastatic hormone-sensitive prostate cancer, androgen deprivation therapy is the backbone rather than the whole treatment. Current guidelines favour adding an androgen-receptor pathway inhibitor such as abiraterone, apalutamide, enzalutamide or darolutamide when appropriate. In selected men — particularly with de novo high-volume or high-risk disease who are fit for chemotherapy — triplet treatment using ADT, an androgen-receptor pathway inhibitor and docetaxel may be discussed.

The choice is individualized because the additional drugs have different cardiovascular, metabolic, liver, neurological, blood-pressure and drug-interaction profiles. Treatment intensity should match both the cancer burden and the patient’s ability to tolerate therapy. ADT alone is now mainly reserved for patients who cannot or do not wish to receive treatment intensification.

Local treatment in low-volume metastatic disease

In men who present with a relatively low metastatic burden, radiotherapy to the prostate can improve outcomes when added to systemic treatment. This does not mean every metastatic patient should receive prostate surgery or radiation. The benefit depends on disease volume and the clinical setting, and local treatment does not replace systemic therapy. Metastasis-directed radiotherapy to a few metastatic deposits is also an active research area and is used selectively rather than as a substitute for proven systemic treatment.

What genetic results can change for you and your family

Inherited and tumour-based testing can influence both family counselling and future treatment. Alterations in DNA-repair genes such as BRCA1/2 may create eligibility for PARP-inhibitor strategies in appropriate disease settings. Other molecular findings can occasionally direct immunotherapy or clinical-trial options. Testing is most useful when accompanied by counselling about what a germline result could mean for close relatives.

How metastatic disease is followed

PSA is important, but modern metastatic treatment should not be judged by PSA alone. Symptoms, examination, blood counts, kidney/liver function, alkaline phosphatase when relevant, testosterone while on ADT and interval imaging all contribute. Some men can develop radiographic progression without a dramatic PSA rise, particularly on potent androgen-receptor pathway treatment.

A new pain pattern, declining function or neurological symptom should therefore be reported even if the last PSA looked stable. Follow-up frequency is usually closer during the first months of a new systemic treatment and can be spaced once the response and side-effect profile are established.

Choosing the next treatment after castration resistance develops

Castration-resistant prostate cancer means the cancer is progressing despite testosterone being adequately suppressed. ADT is usually continued, but another treatment is added or changed. Options may include chemotherapy, a different mechanism of androgen-pathway treatment, PARP-inhibitor strategies for selected DNA-repair alterations, radioligand therapy such as lutetium-177 PSMA in appropriate PSMA-positive disease, radium-223 for selected bone-predominant disease, or clinical trials.

The sequence matters. Simply switching repeatedly between similar androgen-receptor drugs may be less effective than changing treatment class when resistance develops. Previous treatments, speed of progression, symptoms, marrow reserve, molecular results and access all influence the next choice.

Consultation checklist

  • Biopsy report and Grade Group.
  • PSA history and current testosterone if already on ADT.
  • PSMA PET/CT, CT and bone imaging reports and actual images.
  • Full list of previous prostate-cancer treatments with dates.
  • Blood counts, kidney/liver function, alkaline phosphatase and relevant metabolic tests.
  • Germline or tumour genetic testing if done.
  • Current pain medicines, cardiovascular history and bone-health records.

FAQs

Is metastatic prostate cancer curable?

Widespread metastatic disease is usually considered controllable rather than curable, but modern treatment can produce long periods of disease control. Selected oligometastatic situations are an area of evolving treatment.

Why is ADT alone often not enough now?

Multiple trials have shown better outcomes when ADT is combined early with an androgen-receptor pathway inhibitor and, in selected men, chemotherapy.

Does every patient need chemotherapy?

No. Age, fitness, disease volume, symptoms, prior treatment and preference all affect the choice. Many men receive effective non-chemotherapy intensification.

Will bone metastases always cause pain?

No. Some are found on scans before symptoms develop.

Should my family be tested if I have metastatic prostate cancer?

Not automatically, but germline testing is often appropriate in metastatic disease. If an inherited pathogenic variant is found, genetic counselling can guide testing of relatives.

Is ADT alone enough for newly diagnosed metastatic prostate cancer?

For many fit men, current practice uses ADT together with another life-prolonging treatment. ADT alone may still be appropriate when combination therapy is unsuitable or declined.

Related reading

References

Note: This information is for educational purposes only and is not a substitute for medical advice. Please consult your doctor for any symptoms.